Spotlight Growth
No Result
View All Result
Wednesday, February 8, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Geron (NASDAQ: GERN) Reports Positive Results From IMerge Phase 3 Trial of Imetelstat for Lower Risk MDS

by admin
January 4, 2023
in Bio/Med/Pharma
0
Geron Corporation NASDAQ GERN Phase 3 IMerge Imetelstat Spotlight Growth

Geron Corporation NASDAQ GERN Phase 3 IMerge Imetelstat Spotlight Growth

Geron Corporation (NASDAQ: GERN) is engaged as a late-stage biopharmaceutical company, which is focused on the research and development of treatments for patients suffering from hematologic malignancies. Shares of the late-stage biopharma company are rallying 37% through early trading on Wednesday, January 4, 2023. Over the past three months, Geron has seen average daily volume of 3.99 million shares. However, volume of 94.41 million shares or dollar volume of around $311.55 million, has already exchanged hands through early trading.

Shares of Geron are gaining after the company reported positive top-line and secondary endpoint results from its IMerge Phase 3 clinical trial of Imetelstat for the treatment of lower risk myelodysplastic syndromes (MDS) who have relapsed, refractory or are not eligible for erythropoiesis stimulating agents (ESAs).

The IMerge Phase 3 trial was a double-blind, 2:1 randomized, placebo-controlled clinical trial. During the trial’s first 8 weeks, patients treated with Imetelstat saw very statistically significant improvements compared to the placebo group. After eight weeks, Imetelstat patients saw a transfusion independence (TI) reading of 47 compared to 9 in the placebo group. This met the primary endpoints for the Phase 3 trial. Over a 24-week period, Imetelstat patients saw a TI reading of 33, compared to the placebo group’s 2 result.

This shows that Imetelstat-treated patients were able to achieve transfusion independent broadly among lower risk MDS subtypes. Average hemoglobin levels in Imetelstat patients saw a robust increase over time compared to the placebo group. In additional, test groups saw clinically-meaningful average reduction in RBC transfusion units compared to the placebo group.

Imetelstat maintained a very strong safety profile throughout the clinical trial. Treatment emergent adverse events (TEAEs) that were seen in the IMerge Phase 3 trial were consistent with the known potential safety risks of the treatment. No new safety issues were found.

Moving forward, Geron Corporation says it plans to submit a New Drug Application with the U.S. Food and Drug Administration, as well as a Marketing Authorization Application (MAA) with EU regulators during the second half of 2023. Geron estimates commcerical launch of Imetelstat to take place sometime during the first half of 2024 in the U.S. and by the end of 2024 in the EU.

“Today is a great day for lower risk MDS patients who are living with the burden of transfusions. The results from the IMerge Phase 3 study were resoundingly positive, presenting compelling durability of transfusion independence, delivering on the promise of imetelstat and telomerase inhibition for these patients,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer. “This milestone is the first of many upcoming catalysts for Geron, with planned U.S. and EU regulatory submissions in 2023, as well as preparations for a potential U.S. commercial launch. In addition, in 2024, we expect an interim analysis of the IMpactMF Phase 3 trial of imetelstat in relapsed/refractory myelofibrosis.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

Tags: biopharmabiopharmaceuticalsbiotechbiotech stocksbiotechnologyclinical trial resultsclinical trialscommon stockday tradingdow jones todayemerging growthFDAFDA newsGERNGERN stockGeronGeron CorporationImerge Phase 3investinginvesting newsinvestmentmedicalmicrocap stocksNASDAQnewspharmaceuticalspublic companysmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstocksstocks to watchtradingtreatmentwebull wallstreetbets
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Innovative Eyewear NASDAQ LUCY Lucyd Lyte 2 Smart Glasses Spotlight Growth

Innovative Eyewear (NASDAQ: LUCY) Debuts Lucyd Lyte 2.0 Audio Eyewear Product

February 7, 2023
American Resources Corporation NASDAQ AREC Reduced Debt By 9 Million Spotlight Growth

American Resources Corporation (NASDAQ: AREC) Reduces Debt by Over $9 Million

February 7, 2023
Its All Greek to Me What Are Option Greeks Spotlight Growth

It’s All Greek to Me: What Are Option Greeks and How Do They Impact Traders?

February 6, 2023
Unleashing the Power of 5G The Future of Mobile Technology Spotlight Growth

Unleashing the Power of 5G: The Future of Mobile Technology

February 6, 2023

Recent News

Innovative Eyewear NASDAQ LUCY Lucyd Lyte 2 Smart Glasses Spotlight Growth

Innovative Eyewear (NASDAQ: LUCY) Debuts Lucyd Lyte 2.0 Audio Eyewear Product

February 7, 2023
American Resources Corporation NASDAQ AREC Reduced Debt By 9 Million Spotlight Growth

American Resources Corporation (NASDAQ: AREC) Reduces Debt by Over $9 Million

February 7, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested